John Matthew Collins - Oct 27, 2023 Form 4 Insider Report for CALIX, INC (CALX)

Role
Chief Commercial Ops Officer
Signature
/s/ Tom Gemetti as Attorney-in-Fact for John Matthew Collins
Stock symbol
CALX
Transactions as of
Oct 27, 2023
Transactions value $
-$1,488,900
Form type
4
Date filed
10/30/2023, 05:02 PM
Previous filing
Jul 26, 2023
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALX Common Stock Options Exercise $104K +15K $6.95* 15K Oct 27, 2023 Direct
transaction CALX Common Stock Options Exercise $120K +15K +100% $8.03* 30K Oct 27, 2023 Direct
transaction CALX Common Stock Options Exercise $275K +30K +100% $9.16* 60K Oct 27, 2023 Direct
transaction CALX Common Stock Sale -$1.99M -60K -100% $33.14 0 Oct 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALX Stock Option (right to buy) Options Exercise $0 -15K -42.65% $0.00 20.2K Oct 27, 2023 Common Stock 15K $6.95 Direct F2
transaction CALX Stock Option (right to buy) Options Exercise $0 -15K -37.5% $0.00 25K Oct 27, 2023 Common Stock 15K $8.03 Direct F3
transaction CALX Stock Option (right to buy) Options Exercise $0 -30K -15.38% $0.00 165K Oct 27, 2023 Common Stock 30K $9.16 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold between $32.39 and $34.12 per share at a weighted average price of $33.14. The reporting person will provide full information regarding the number of shares sold at each sale price upon request.
F2 80,000 of the shares subject to the option grant were fully vested and exercisable on July 17, 2021.
F3 45,000 of the shares subject to the option grant were fully vested and exercisable on February 14, 2023.
F4 175,000 of the shares subject to the option grant were fully vested and exercisable on July 31, 2023.